{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:48:32Z","timestamp":1787838512392,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T00:00:00Z","timestamp":1453248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"publisher","award":["Cancer Center Support Grant P30 CA014520"],"award-info":[{"award-number":["Cancer Center Support Grant P30 CA014520"]}],"id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["A8051001"],"award-info":[{"award-number":["A8051001"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00280-016-2958-1","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T07:21:30Z","timestamp":1453274490000},"page":"527-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors"],"prefix":"10.1007","volume":"77","author":[{"given":"Justine Yang","family":"Bruce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M.","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila H.","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth I.","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Shalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Breazna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro D.","family":"Ricart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tortorici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,20]]},"reference":[{"key":"2958_CR1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039\u20132049","journal-title":"N Engl J Med"},{"key":"2958_CR2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841\u2013844","journal-title":"Nature"},{"key":"2958_CR3","unstructured":"Marrone T, Hu-Lowe D, Grazzini M et al (2007) PF-00337210, a potent, selective and orally bioavailable small molecule inhibitor of VEGFR-2. p 3992"},{"key":"2958_CR4","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res Off J Am Assoc Cancer Res 9:327\u2013337","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2958_CR5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"2958_CR6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"2958_CR7","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931\u20131939","journal-title":"Lancet"},{"key":"2958_CR8","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"2958_CR9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2009.25.4359","volume":"28","author":"A Dowlati","year":"2010","unstructured":"Dowlati A (2010) Hunting and trapping the vascular endothelial growth factor. J Clin Oncol Off J Am Soc Clin Oncol 28:185\u2013187","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 24:25\u201335","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdq313","volume":"22","author":"W Fiedler","year":"2011","unstructured":"Fiedler W, Giaccone G, Lasch P et al (2011) Phase I trial of SU14813 in patients with advanced solid malignancies. Ann Oncol 22:195\u2013201","journal-title":"Ann Oncol"},{"key":"2958_CR12","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdi247","volume":"16","author":"SN Holden","year":"2005","unstructured":"Holden SN, Eckhardt SG, Basser R et al (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16:1391\u20131397","journal-title":"Ann Oncol"},{"key":"2958_CR13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/annonc\/mdq599","volume":"22","author":"DJ Jonker","year":"2011","unstructured":"Jonker DJ, Rosen LS, Sawyer MB et al (2011) A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol 22:1413\u20131419","journal-title":"Ann Oncol"},{"key":"2958_CR14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/1078-0432.CCR-09-0694","volume":"16","author":"K Mross","year":"2010","unstructured":"Mross K, Stefanic M, Gmehling D et al (2010) Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 16:311\u2013319","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2958_CR15","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2006.07.8170","volume":"25","author":"LS Rosen","year":"2007","unstructured":"Rosen LS, Kurzrock R, Mulay M et al (2007) Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 25:2369\u20132376","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 23:965\u2013972","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR17","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2005.09.034","volume":"23","author":"AL Thomas","year":"2005","unstructured":"Thomas AL, Morgan B, Horsfield MA et al (2005) Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787\/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol Off J Am Soc Clin Oncol 23:4162\u20134171","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2001","unstructured":"Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol Off J Am Soc Clin Oncol 19:843\u2013850","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR19","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 22:2184\u20132191","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2009.22.9237","volume":"28","author":"AC Lockhart","year":"2010","unstructured":"Lockhart AC, Rothenberg ML, Dupont J et al (2010) Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 28:207\u2013214","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"2958_CR21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh J, Bondarenko IM, Lichinitser MR et al (2012) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol 30(9):921\u2013929","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2009.22.9427","volume":"28","author":"GD Goss","year":"2010","unstructured":"Goss GD, Arnold A, Shepherd FA et al (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol Off J Am Soc Clin Oncol 28:49\u201355","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR23","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2010.29.4496","volume":"29","author":"JR Hecht","year":"2011","unstructured":"Hecht JR, Trarbach T, Hainsworth JD et al (2011) Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol 29:1997\u20132003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","volume":"11","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Saleh MN, Paul D et al (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11:82\u201392","journal-title":"Clin Breast Cancer"},{"key":"2958_CR25","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","volume":"28","author":"G Scagliotti","year":"2010","unstructured":"Scagliotti G, Novello S, von Pawel J et al (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 28:1835\u20131842","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR26","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.2010.33.2429","volume":"29","author":"AF Sobrero","year":"2011","unstructured":"Sobrero AF, Bruzzi P (2011) Vatalanib in advanced colorectal cancer: two studies with identical results. J Clin Oncol Off J Am Soc Clin Oncol 29:1938\u20131940","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR27","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2010.29.5436","volume":"29","author":"E Cutsem Van","year":"2011","unstructured":"Van Cutsem E, Bajetta E, Valle J et al (2011) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787\/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol Off J Am Soc Clin Oncol 29:2004\u20132010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"2958_CR28","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103(9):763\u2013773","journal-title":"J Natl Cancer Inst"},{"key":"2958_CR29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2958_CR30","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1200\/JCO.2005.04.143","volume":"23","author":"G Liu","year":"2005","unstructured":"Liu G, Rugo HS, Wilding G et al (2005) Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol Off J Am Soc Clin Oncol 23:5464\u20135473","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.2517-6161.1980.tb01109.x","volume":"42","author":"P McCullagh","year":"1980","unstructured":"McCullagh P (1980) Regression models for ordinal data (with discussion). J R Stat Soc 42:109\u2013142","journal-title":"J R Stat Soc"},{"key":"2958_CR32","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2010.31.9236","volume":"29","author":"S Postel-Vinay","year":"2011","unstructured":"Postel-Vinay S, Gomez-Roca C, Molife LR et al (2011) Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol Off J Am Soc Clin Oncol 29:1728\u20131735","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2958_CR33","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.1158\/1078-0432.CCR-07-2133","volume":"13","author":"MJ Ratain","year":"2007","unstructured":"Ratain MJ, Glassman RH (2007) Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res Off J Am Assoc Cancer Res 13:6545\u20136548","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2958_CR34","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1158\/1078-0432.CCR-06-2860","volume":"13","author":"BH Goulart","year":"2007","unstructured":"Goulart BH, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA (2007) Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res Off J Am Assoc Cancer Res 13:6719\u20136726","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2958_CR35","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S et al (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res 15:4220\u20134227","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2958_CR36","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","volume":"23","author":"HS Rugo","year":"2005","unstructured":"Rugo HS, Herbst RS, Liu G et al (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol Off J Am Soc Clin Oncol 23:5474\u20135483","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-2958-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-2958-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-2958-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T21:56:37Z","timestamp":1718315797000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-2958-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,20]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["2958"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-2958-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,20]]}}}